BPC-157 vs TB-500
Two research compounds discussed interchangeably for tissue repair. Their mechanisms, their evidence bases and their regulatory positions are not the same.
PRECLINICALEARLY CLINICAL
Read the comparison →
Comparisons
Peptide comparisons
Side-by-side analysis of compounds that are routinely discussed together. Every comparison separates approved drugs from investigational compounds and laboratory research chemicals, because that distinction usually matters more than anything else in the table.
CJC-1295 vs Ipamorelin
Two growth hormone secretagogues with different receptors and very different evidence. One has Phase 1 hormone data; the other has a published Phase 2 trial that missed its endpoint.
EARLY CLINICALEARLY CLINICAL
Read the comparison →
Semaglutide vs Tirzepatide vs Retatrutide
One, two and three receptors. Two approved drugs and one investigational compound. What the trials measured, what the labels say, and where the differences actually lie.
CLINICALCLINICALCLINICAL
Read the comparison →
Tesamorelin vs CJC-1295
Two GHRH analogs with the same upstream mechanism and completely different evidence. What separates an approved medicine from a discontinued research compound.
CLINICALEARLY CLINICAL
Read the comparison →